Drug Trial Radar · NCT06963710
A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)
Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Jul 15, 2025
Primary completion
Mar 2027
Study completion Aug 2028
Sponsor
- Lead sponsor
- Aligos TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- May 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2 study to evaluate efficacy and safety of 48 weeks of oral once daily monotherapy with ALG-000184 versus tenofovir disproxil fumarate (TDF) for chronic HBV infection.
Conditions
- Chronic Hepatitis B Infection
Interventions
ALG-000184Drug
300 mg tablet
TDFDrug
300 mg tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- HBeAg positive: HBV DNA <Lower Limit of Quantification [LLOQ] (10 IU/mL, target detected or target not detected)Time frame: 48 weeks
- HBeAg negative: HBV DNA <Lower Limit of Quantification [LLOQ] (10 IU/mL, target not detected)Time frame: 48 weeks
Locations
41 sites in 14 countries. Site status is shown where the registry gives one.
Aligos Investigational Site
Coronado, California
Aligos Investigational Site
Pasadena, California
Aligos Investigational Site
Rialto, California
Aligos Investigational Site
San Francisco, California
Aligos Investigational Site
San Jose, California
Aligos Investigational Site
Miami, Florida
Aligos Investigational Sites
Sofia, Bulgaria
Aligos Investigational Site
Edmonton, Canada
Aligos Investigational Site
Ottawa, Canada
Aligos Investigational Site
Toronto, Canada
Aligos Investigational Sites
Vancouver, Canada
Aligos Investigational Sites
Beijing, China
Aligos Investigational Site
Changchun, China
Aligos Investigational Site
Chengdu, China
Aligos Investigational Site
Chongqing, China
Aligos Investigational Sites
Guangzhou, China
Aligos Investigational Site
Nanjing, China
Aligos Investigational Sites
Shanghai, China
Aligos Investigational Site
Clichy, France
Aligos Investigational Site
Limoges, France
Aligos Investigational Site
Nice, France
Aligos Investigational Site
Toulouse, France
Aligos Investigational Sites
Hong Kong, Hong Kong
Aligos Investigational Site
Milan, Italy
Aligos Investigational Site
Chisinau, Moldova
Aligos Investigational Site
Auckland, New Zealand
Aligos Investigational Sites
Bucharest, Romania
Aligos Investigational Site
Ansan, South Korea
Aligos Investigational Site
Busan, South Korea
Aligos Investigational Sites
Seoul, South Korea
Aligos Investigational Site
Ulsan, South Korea
Aligos Investigational Site
Yangsan, South Korea
Aligos Investigational Site
Pontevedra, Spain
Aligos Investigational Site
Chiayi City, Taiwan
Aligos Investigational Site
Kaohsiung City, Taiwan
Aligos Investigational Site
Taichung, Taiwan
Aligos Investigational Site
Tainan, Taiwan
Aligos Investigational Site
Taipei, Taiwan
Aligos Investigational Site
Glasgow, United Kingdom
Aligos Investigational Site
Leicester, United Kingdom
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.